Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1997 Nov;110(2):296–302. doi: 10.1111/j.1365-2249.1997.tb08331.x

Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10

T KUCHARZIK *, N LÜGERING *, G WINDE *, W DOMSCHKE *, R STOLL *
PMCID: PMC2265515  PMID: 9367416

Abstract

Cytokines released from tumour cells may have function as signals to neighbouring immune and inflammatory cells. Several studies have shown that the immunoregulatory cytokines IL-10 and transforming growth factor-beta 1 (TGF-β1) as well as prostaglandin-E2 (PGE2) play an important role in tumour-induced immunosuppression. The aim of the study was to investigate the effect of colon carcinoma cell lines on IL-10 production in peripheral monocytes (PBMC) and lamina propria mononuclear cells (LPMC). We examined four colon carcinoma cell lines (HT-29, Caco-2, Colo-320 and HCT-116) and determined their production of TGF-β1, IL-10 and PGE2. Peripheral monocytes were isolated by density gradient centrifugation and LPMC were isolated from surgical specimens using a collagenase digestion method. Monocytes and LPMC were cultured with colon carcinoma cell conditioned medium or in co-culture with colon carcinoma cells. Supernatants were then determined for the production of IL-10 by ELISA assays. All colon carcinoma cell lines stimulated peripheral monocytes as well as LPMC to produce markedly increased levels of IL-10. Colon cancer cells secreted negligible levels of IL-10, but high amounts of TGF-β1 and PGE2. Neutralization of TGF-β1 by administration of anti-TGF-β as well as neutralization of PGE2 with anti-PGE2 antisera reduced the IL-10 production of monocytes markedly, indicating that tumour cell-derived TGF-β1 and PGE2 are major factors for IL-10 stimulation. In vitro stimulation of monocytes with TGF-β1 and PGE2 could confirm that TGF-β1 as well as PGF2 at picogram concentrations were able to prime monocytes for enhanced IL-10 production. Our results demonstrate that colon carcinoma cell lines enhance the ability of monocytes and intestinal macrophages to produce IL-10. The stimulation of monocyte IL-10 by colon cancer cell-derived TGF-β1 and PGE2 may act as a tumour-protecting mechanism by impairing the activation of anti-tumour cytokines.

Keywords: IL-10, transforming growth factor-beta 1, prostaglandin E2, colon carcinoma cell lines, carcinogenesis

Full Text

The Full Text of this article is available as a PDF (766.3 KB).

References

  • 1.Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res. 1993;60:247–67. doi: 10.1016/s0065-230x(08)60827-1. [DOI] [PubMed] [Google Scholar]
  • 2.Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol. 1995;155:4924–32. [PubMed] [Google Scholar]
  • 3.Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J Immunol. 1996;156:73–78. [PubMed] [Google Scholar]
  • 4.Bost KL, Bieligk SC, Jaffe BM. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol. 1995;154:718–29. [PubMed] [Google Scholar]
  • 5.Nabioullin R, Sone S, Mizuno K, Yano S, Nishioka Y, Haku T, Okura T. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leuc Biol. 1994;55:437–42. doi: 10.1002/jlb.55.4.437. [DOI] [PubMed] [Google Scholar]
  • 6.Alleva DG, Burger CJ, Elgert KD. Tumor induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol. 1994;153:1674–86. [PubMed] [Google Scholar]
  • 7.Awad AB, Kamei A, Horvath PI, Fink CS. Prostaglandin synthesis in human cancer cells: influence of fatty acids and butyrate. Prost Leukot Essent Fatty Acids. 1995;53:87–93. doi: 10.1016/0952-3278(95)90134-5. [DOI] [PubMed] [Google Scholar]
  • 8.Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:518–23. [PubMed] [Google Scholar]
  • 9.Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4 and interleukin-10. Ann NY AcadSci. 1993;685:713–39. doi: 10.1111/j.1749-6632.1993.tb35934.x. [DOI] [PubMed] [Google Scholar]
  • 10.Moore KW, O'Garra A, Malefyt RW, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol. 1993;11:165–90. doi: 10.1146/annurev.iy.11.040193.001121. [DOI] [PubMed] [Google Scholar]
  • 11.Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease. Clin Exp Immunol. 1995;100:452–6. doi: 10.1111/j.1365-2249.1995.tb03721.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Marchant A, Deviere J, Byl B, De Groote D, Vincent IL, Goldman M. Interleukin-10 production during septicaemia. Lancet. 1993;343:707–8. doi: 10.1016/s0140-6736(94)91584-9. [DOI] [PubMed] [Google Scholar]
  • 13.Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82:2169–74. [PubMed] [Google Scholar]
  • 14.Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int I Cancer. 1993;55:96–101. doi: 10.1002/ijc.2910550118. [DOI] [PubMed] [Google Scholar]
  • 15.Masood R, Zhang Y, Bond MW, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome related B-cell lymphoma. Blood. 1995;85:3423–30. [PubMed] [Google Scholar]
  • 16.Lamprecht SA, Schwartz B, Glicksman A. Transforming growth factor-beta in intestinal epithelial differentiation and neoplasia (review) Anticancer Res. 1989;9:1877–81. [PubMed] [Google Scholar]
  • 17.Messague J. The TGF-β family of growth and differentiation factors. Cell. 1976;49:683–705. doi: 10.1016/0092-8674(87)90443-0. [DOI] [PubMed] [Google Scholar]
  • 18.Roberts AB, Thompson NL, Heine U, Fanders C, Sporn MB. Transforming growth factor-β: possible roles in carcinogenesis. Br J Cancer. 1988;57:594–600. doi: 10.1038/bjc.1988.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Anzano MA, Rieman D, Prichett W, Bowen DF, Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res. 1989;49:2898–904. [PubMed] [Google Scholar]
  • 20.Sun L, Wu S, Coleman K, Fields KC, Humphrey LE, Brattain MG. Autocrine transforming growth factor-beta 1 and beta 2 expression is increased by cell crowding and quiescence in colon carcinoma cells. Exp Cell Res. 1994;214:215–24. doi: 10.1006/excr.1994.1251. [DOI] [PubMed] [Google Scholar]
  • 21.Gorelik L, Prokhonova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Thl-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1994;39:117–26. [PubMed] [Google Scholar]
  • 22.Weiskirch LM, Bar-Dagan Y, Mokyr MB. Transforming growth factor–mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother. 1994;38:215–24. doi: 10.1007/BF01533512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Honn KV, Bockman RS, Marnett LJ. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins. 1981;21:833–50. doi: 10.1016/0090-6980(81)90240-9. [DOI] [PubMed] [Google Scholar]
  • 24.Feige U, Overwien B, Sorg C. Purification of human blood monocytes by hypotonic density gradient centrifugation in Percoll. J Immunol Methods. 1982;54:309–15. doi: 10.1016/0022-1759(82)90315-5. [DOI] [PubMed] [Google Scholar]
  • 25.Kucharzik T, Lügering N, Weigelt H, Adolf M, Domschke W, Stoll R. Immunoregulatory properties of interleukin-13 in patients with inflammatory bowel disease. Comparison with interleukin-4 and interleukin-10. Clin Exp Immunol. 1996;104:483–90. doi: 10.1046/j.1365-2249.1996.39750.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bull DM, Bookman MA. Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest. 1977;59:966. doi: 10.1172/JCI108719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.de Waal Malefyt R, Abrams J, Bennet B, Figdor CG, De Vries IE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–20. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Van der Pouw TCTM, Boeije LCM, Smeenk RIT, Wijdenes J, Arden LA. Prostaglanding is a potent inhibitor of human interleukin-12 production. J Exp Med. 1995;181:775–9. doi: 10.1084/jem.181.2.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Li X-F, Takiuchi H, Zou J-P, et al. Transforming growth factor- (TGF-)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-0 and a progressive increase in TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn Cancer Res. 1993;84:315–25. doi: 10.1111/j.1349-7006.1993.tb02873.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375–82. doi: 10.1053/gast.1996.v110.pm8566583. [DOI] [PubMed] [Google Scholar]
  • 31.Reddy BS, Nayini I, Tokumo K, Rigotty I, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,1-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990;50:2562–8. [PubMed] [Google Scholar]
  • 32.Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. I Leuc Biol. 1993;54:613–26. doi: 10.1002/jlb.54.6.613. [DOI] [PubMed] [Google Scholar]
  • 33.Wahl S, Hunt DA, Wakefield LM, Mc Cartney-Francis N, Wahl LM, Roberts AB, Spom MB. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA. 1987;84:5788–92. doi: 10.1073/pnas.84.16.5788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES